ALGS

Aligos is a pre-revenue, clinical-stage biotech whose value is entirely optionality on three Phase 1/2 assets (pevifoscorvir sodium for chronic HBV, ALG-055009 for MASH/obesity, ALG-097558 for coronaviruses), not on its financials. The financials themselves are alarming: the 10-K states outright that the operating plan 'raise[s] doubt about our ability to continue as a going concern for at least 12 months' and that existing cash funds operations only 'into the third quarter of 2026' — i.e., the company likely runs out of money within roughly one quarter of the analysis date. With $18.3M cash against an $82.5M annual operating burn (and R&D alone at $69.5M), the runway math is unforgiving; management explicitly warns it must either raise capital or 'significantly curtail our operations.' The tiny $34.5M market cap on 6.18M shares (after a ~92% share-count reduction, i.e. a reverse split) tells you the market is pricing distress.

The headline that net loss 'improved' 81.6% YoY to -$24.2M is misleading: operating loss was essentially flat at -$88.0M, so the smaller net loss reflects non-operating/one-time items, not a healthier business. Revenue is de minimis and shrinking (-39.5% to $2.19M), making the 15.8x P/S meaningless. Equity swung positive largely because liabilities fell 64.7%, but the accumulated deficit of -$642M underscores how much cash this platform has consumed with no product yet approved. Every operating metric — margin, ROE, cash trend (-50.5%) — is deeply negative.